Payment overview · 2025
General Payments
$796.53
42 reported records · 13 companies
Healthcare provider profile · identity verified
Edwin Santos, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CAMPTON, KY · NPI 1689652281
Verified facts
What the public records show
CMS Open Payments records show Edwin Santos, M.D. received $796.53 in general payments during 2025 across 42 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 30.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Mounjaro, Rexulti, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rexulti by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported APTIOM as an associated drug or biological on 11 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Aptiom by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $240.02 | 30.1% | 15 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $155.07 | 19.5% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $110.34 | 13.8% | 6 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $55.29 | 6.9% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $44.87 | 5.6% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $39.94 | 5.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.08 | 4.3% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.36 | 3.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $21.16 | 2.7% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $18.18 | 2.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.49 | 2.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.90 | 2.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.83 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $796.53 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $240.02 | 15 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $139.21 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $123.71 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $110.34 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $107.85 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $55.29 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $44.87 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $39.94 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.08 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $31.36 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $21.16 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 77 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 74 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
77 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
20 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
74 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
12 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
74 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
87 | 16 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | APTIOM open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 11 recipient NPIs · example record 1176658319 |
Aptiom · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1237 | 175 |
| Gabapentin | Gabapentin | 548 | 107 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 530 | 129 |
| Levothyroxine Sodium | Levothyroxine Sodium | 468 | 124 |
| Alprazolam | Alprazolam | 441 | 69 |
| Lisinopril | Lisinopril | 373 | 106 |
| Atorvastatin Calcium | Atorvastatin Calcium | 369 | 103 |
| Pantoprazole Sodium | Pantoprazole Sodium | 327 | 81 |
| Clonazepam | Clonazepam | 294 | 43 |
| Lorazepam | Lorazepam | 267 | 42 |
| Omeprazole | Omeprazole | 259 | 70 |
| Montelukast Sodium | Montelukast Sodium | 252 | 76 |
| Sertraline Hcl | Sertraline Hcl | 251 | 72 |
| Furosemide | Furosemide | 237 | 68 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 235 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 229 | 64 |
| Losartan Potassium | Losartan Potassium | 226 | 69 |
| Diazepam | Diazepam | 224 | 36 |
| Metformin Hcl | Metformin Hcl | 198 | 58 |
| Glipizide Er | Glipizide | 182 | 46 |
| Pregabalin | Pregabalin | 176 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 175 | 37 |
| Eliquis | Apixaban | 174 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 171 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 156 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 148 | 33 |
| Prednisone | Prednisone | 148 | 80 |
| Hydrochlorothiazide | Hydrochlorothiazide | 132 | 40 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 130 | 17 |
| Simvastatin | Simvastatin | 129 | 39 |
| Tramadol Hcl | Tramadol Hcl | 123 | 28 |
| Azithromycin | Azithromycin | 118 | 90 |
| Famotidine | Famotidine | 118 | 26 |
| Trazodone Hcl | Trazodone Hcl | 108 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 104 | 24 |
| Carvedilol | Carvedilol | 100 | 28 |
| Donepezil Hcl | Donepezil Hcl | 98 | 22 |
| Mirtazapine | Mirtazapine | 88 | 24 |
| Ozempic | Semaglutide | 87 | 16 |
| Xarelto | Rivaroxaban | 85 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 83 | 34 |
| Memantine Hcl | Memantine Hcl | 81 | 16 |
| Potassium Chloride | Potassium Chloride | 80 | 24 |
| Methenamine Hippurate | Methenamine Hippurate | 78 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 78 | 13 |
| Farxiga | Dapagliflozin Propanediol | 77 | 16 |
| Jardiance | Empagliflozin | 74 | 18 |
| Spironolactone | Spironolactone | 74 | 19 |
| Ezetimibe | Ezetimibe | 71 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 28 |
| Ondansetron Odt | Ondansetron | 62 | 27 |
| Ventolin Hfa | Albuterol Sulfate | 62 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 20 |
| Meloxicam | Meloxicam | 60 | 20 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 58 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | 12 |
| Atenolol | Atenolol | 51 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 33 |
| Mounjaro | Tirzepatide | 51 | suppressed |
| Roflumilast | Roflumilast | 50 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 48 | 18 |
| Baclofen | Baclofen | 47 | suppressed |
| Fluconazole | Fluconazole | 47 | 31 |
| Oxycodone Hcl | Oxycodone Hcl | 47 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 47 | 16 |
| Allopurinol | Allopurinol | 46 | 15 |
| Methadone Hcl | Methadone Hcl | 46 | suppressed |
| Ibuprofen | Ibuprofen | 45 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 44 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 16 |
| Buspirone Hcl | Buspirone Hcl | 40 | suppressed |
| Celecoxib | Celecoxib | 40 | 16 |
| Methocarbamol | Methocarbamol | 40 | 13 |
| Levofloxacin | Levofloxacin | 39 | 32 |
| Phenobarbital | Phenobarbital | 39 | suppressed |
| Sucralfate | Sucralfate | 39 | suppressed |
| Topiramate | Topiramate | 39 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 39 | suppressed |
| Entresto | Sacubitril/Valsartan | 38 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 37 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 36 | suppressed |
| Synthroid | Levothyroxine Sodium | 36 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Gemtesa | Vibegron | 35 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 35 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 34 | suppressed |
| Bumetanide | Bumetanide | 34 | suppressed |
| Nifedipine Er | Nifedipine | 34 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 12 |
| Fenofibrate | Fenofibrate | 33 | 14 |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Nitroglycerin | Nitroglycerin | 30 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 28 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 27 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 20 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 25 |
| Elmiron | Pentosan Polysulfate Sodium | 24 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Levemir Flexpen | Insulin Detemir | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Cefdinir | Cefdinir | 20 | 20 |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 20 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 19 | suppressed |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 18 | 18 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Loperamide | Loperamide Hcl | 18 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 17 | suppressed |
| Novolin R | Insulin Regular, Human | 17 | suppressed |
| Rexulti | Brexpiprazole | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 16 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 13 |
| Glimepiride | Glimepiride | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Budesonide | Budesonide | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | 11 |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Constulose | Lactulose | 11 | suppressed |
| Humulin R | Insulin Regular, Human | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $796.53 · 42 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AIRSUPRA, BREZTRI, CAPLYTA, CRYSVITA, Cologuard Collection Kit, FARXIGA, GEMTESA, JARDIANCE, Kerendia, MOUNJARO, REPATHA, REXULTI, TRELEGY ELLIPTA, XIFAXAN, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error